Core Viewpoint - The company, Weigao Blood Purification, has shown a stable performance in the medical device industry, with a notable market share in blood purification products and a competitive valuation compared to industry peers [1][2]. Company Summary - Weigao Blood Purification's stock closed at 40.78 yuan, up 2.49%, with a rolling PE ratio of 36.66, marking a new low in 58 days, and a total market capitalization of 16.777 billion yuan [1]. - The company specializes in the research, production, and sales of blood purification medical products, including hemodialysis devices, dialysis tubing, dialysis machines, and peritoneal dialysis solutions [1]. - In 2022, Weigao held the largest market share in China for hemodialysis devices at 32.5% and for dialysis tubing at 32.8%. It ranked fifth in the peritoneal dialysis solution market with a 3.6% share [1]. Industry Summary - The average PE ratio for the medical device industry is 54.79, with a median of 37.86, positioning Weigao at the 72nd rank within the industry [1]. - The latest quarterly report for Q1 2025 shows the company achieved a revenue of 896 million yuan, a year-on-year increase of 6.44%, and a net profit of 112 million yuan, up 7.91%, with a gross margin of 40.92% [2]. - The company is one of 50 institutions holding shares in Weigao, with a total holding of 0.73 million shares valued at 0.00 billion yuan [1].
威高血净收盘上涨2.49%，滚动市盈率36.66倍，总市值167.77亿元